Supplement Engine
Melatonin
N-acetyl-5-methoxytryptamine
Sleep & Recovery
Chronobiotic
Conditional
Summary: Melatonin is a clock-setting hormone, not a sleeping pill — but most people take enough to flood their receptors 100 times over what their body would ever produce naturally. The sweet spot is 0.3–1 mg in the early evening for circadian use, not 10 mg at bedtime. Even worse: 71% of OTC produ
Think of your brain as having a master clock — a tiny region that coordinates your entire 24-hour rhythm. Melatonin is that clock's "the day is ending" signal. Taking 0.3 mg two hours before sleep gently tells the clock to advance its schedule. Taking 10 mg at bedtime is like flooding a precision instrument with 100 times the signal it was built to detect — the clock gets confused, your receptors go numb, and you wake up groggy from the chemical overload, not refreshed from the sleep shift.
That's the general answer. Your stack is different.
Check your whole stackN-acetyl-5-methoxytryptamine
The Plain English Version
Your melatonin dose is probably 10 times too high — and it's making your sleep biology worse.
Think of your brain as having a master clock — a tiny region that coordinates your entire 24-hour rhythm. Melatonin is that clock's "the day is ending" signal. Taking a small amount two hours before sleep gently tells the clock to shift its schedule forward. Taking the standard 10 mg tablet at bedtime is like flooding a precision instrument with 100 times the signal it was built to detect — your receptors go numb, you get artificially drowsy, but the underlying clock stays confused, and you wake up groggy rather than rested.
Want the full evidence? Keep scrolling
What People Claim
"Melatonin is a natural sleep hormone your body already makes — supplementing it is just topping up what screens and stress have depleted. More is better. 10 mg tablets give you premium high-strength sleep support. It's gentle, safe for daily use, safe for kids, and an all-natural alternative to sleeping pills."
Beyond sleep, melatonin is promoted for jet lag recovery, shift work adaptation, exercise recovery, anti-aging via antioxidant properties, and as a natural growth hormone booster. The implicit message: because it's endogenous and sold over the counter, chronic use at any dose is risk-free.
The result is a market dominated by 5–10 mg "premium" tablets — a dose 10 to 100 times above what the pharmacology literature supports for circadian use.
What the Evidence Shows
| Claimed Benefit | Evidence | Effect | Verdict |
|---|---|---|---|
| Jet lag prevention STRONG | Cochrane (10 RCTs) — Herxheimer & Petrie 2002/2006 | NNT = 2; symptom score WMD 38/100 | Works — best indication |
What would change this: None needed — this is already STRONG. Larger RCTs with objective sleep staging would upgrade biomarker confidence. |
|||
| Sleep latency reduction (acute) MODERATE | Multiple RCTs; George et al. 2025 | Significant reduction vs placebo — dose and timing critical | Works when dosed correctly |
What would change this: Head-to-head RCT comparing 0.3 mg vs 5 mg vs 10 mg with PSG-verified sleep latency measurement and DLMO-anchored timing. |
|||
| Delirium prevention (elderly/hospitalised) MODERATE | George et al. 2025 meta-analysis | RR = 0.60 (95% CI: 0.47–0.76) | Promising — evidence supports |
What would change this: Dedicated multi-centre RCT in ICU populations with 90-day follow-up and mortality endpoints. |
|||
| Shift work adaptation MODERATE | Multiple RCTs — mechanistically sound | Variable — light exposure often overpowers | Conditional |
What would change this: RCT controlling light environment alongside melatonin dosing in rotating shift workers — isolating the hormone's contribution. |
|||
| Athletic recovery (evening) MODERATE | López-Flores et al. 2018 (18 articles) | Reduced creatine kinase; improved sleep quality | Conditional — evening only |
What would change this: Controlled trial separating sleep quality improvements from direct tissue-recovery effects using matched sleep controls. |
|||
| Acute athletic performance DEBUNKED | López-Flores et al. 2018 systematic review | No improvement; daytime use impairs performance | Does not work — can backfire |
What would change this: Nothing currently proposed — evidence consistently negative for performance enhancement. |
|||
| Chronic insomnia management WEAK | Nnadi et al. 2025 (N=130,828, observational); no long-term RCT | No robust benefit; 90% higher HF risk signal (confounded) | Insufficient evidence |
What would change this: ≥3-year double-blind RCT with PSG-verified insomnia diagnosis, matching for cardiovascular comorbidities and sleep disorder severity. |
|||
| Anti-aging / antioxidant EMERGING | Anonymous PMC 2025 (N=81, uncontrolled); hypothesis-generating | Only at supraphysiological 40–200 mg doses | Unproven at standard doses |
What would change this: Placebo-controlled RCT at physiological doses with longevity biomarkers (telomere length, oxidative stress markers) over ≥2 years. |
|||
The OTC Quality Crisis
An independent analysis of 31 OTC melatonin supplements found that 71% missed their label claim by more than 10%. Actual content ranged from 83% less to 478% more than stated. Worse: 26% were contaminated with serotonin — an entirely different neurochemical with its own effects. When the product is lying about what's in it, dosing guidance becomes fiction. STRONG — analytical data
How It Works
The Master Clock Pathway
Melatonin is synthesized by the pineal gland from tryptophan. Its primary function is not sedation — it's precision timekeeping. It speaks to two receptor types in your brain's master clock (the suprachiasmatic nucleus, or SCN).
MT1 Receptor — The Drowsiness Signal
Inhibits SCN neuronal firing — dampens the "stay awake" command your circadian clock broadcasts. This produces the sleepiness effect. High doses flood this receptor, which is why OTC megadoses cause sedation. But this is NOT clock-shifting.
MT2 Receptor — The Clock-Shifting Signal
This is the chronobiotic pathway — it phase-shifts the master clock when melatonin arrives at the right concentration and time. Taking 0.3–1 mg at 6 PM tells the clock "the day is ending early" and advances your sleep timing over the next 1–3 days.
Why the Dose Matters So Much
Standard oral tablets (5–10 mg) suffer from severe first-pass breakdown in the liver via the CYP1A2 enzyme — only about 15% reaches your bloodstream, with massive variation between people. Sublingual (dissolved under the tongue) and spray formulations bypass the liver entirely, achieving 80–95% absorption. For the MT2 clock-shifting pathway, you need the right dose at the right time — flooding it with 10x excess blocks the signal rather than transmitting it clearly.
Timing Is Everything
Taking melatonin at 6 PM signals "it's getting dark" → advances your sleep phase. Taking it at 11 PM signals "it's already night" → maintains your phase without shifting it. Taking large doses at bedtime forces sedation via MT1 without the MT2 clock-shift — you get drowsy but your underlying rhythm stays misaligned. This is why jet lag requires melatonin at the destination's local bedtime, not your home timezone's.
The Debate
Nnadi et al. 2025 — AHA Scientific Sessions — N=130,828
Propensity-matched observational study finds 90% higher heart failure risk and doubled mortality in chronic melatonin users compared to non-users.
Anonymous PMC 2025 — N=81 — Uncontrolled
Long-term high-dose melatonin (40–200 mg) in elderly with comorbidities shows improved hypertension and ischemic heart disease markers over years of use.
Why they disagree: The AHA cohort had severe refractory insomnia — a condition that itself is a powerful independent driver of cardiovascular disease. Confounding by indication: people with bad enough insomnia to use melatonin chronically are already at higher CVD risk. The small uncontrolled study used supraphysiological anti-oxidative megadoses in a completely different population. Same molecule; different doses, populations, and mechanisms. The current evidence supports hypothesis-generating only — no established causal cardiovascular risk at standard doses.
OTC Industry Position
5–10 mg tablets are standard and effective — they help people fall asleep. High-strength formulations are popular because consumers report them working.
Pharmacokinetic Evidence — Multiple Trials
0.3–0.5 mg replicates physiological nocturnal peaks and is pharmacologically superior for phase-shifting. Higher doses cause receptor desensitization and worsen circadian biology.
Why they disagree: OTC dosing was benchmarked on sedative effect (MT1 receptor flooding), not chronobiotic optimization (MT2 receptor precision). Higher doses appear to "work" for sleep onset — they force drowsiness — but actively counter the underlying circadian shifting that makes melatonin medically useful. The evidence is consolidating strongly around low-dose precision for circadian use.
Real World vs Lab
Lab
Studies use verified, pharmacist-compounded melatonin at exact doses confirmed by independent assay.
Real World
71% of OTC products miss their label claim by more than 10%. Content ranges from 83% less to 478% more than stated. 26% contain serotonin — a different active compound entirely. Formulation sourcing matters as much as the dosing decision.
Lab
Doses administered relative to each subject's precisely measured DLMO (Dim Light Melatonin Onset) — the moment their body's own melatonin starts rising.
Real World
Consumers take melatonin at arbitrary times with no knowledge of their personal circadian phase. A night owl with a naturally delayed rhythm taking 1 mg at 9 PM may actually worsen their misalignment if their body clock is already running late. "Take before bed" is imprecise without knowing when the clock thinks bedtime is.
Lab
Controlled lighting conditions — participants in dim light before and after dosing, preventing light from suppressing the melatonin signal.
Consumers take melatonin while using bright phone screens, watching television, or under overhead LED lighting — all of which actively suppress endogenous melatonin production and blunt the chronobiotic effect of the exogenous dose. The supplement cannot overcome a phone in your face.
Exactly How to Use It
| Who | Dose | Timing | Form | Notes |
|---|---|---|---|---|
| Jet lag (eastbound travel ≥5 time zones) | 0.5–5 mg | At destination bedtime, night of travel + 3–4 nights | Oral IR or sublingual | Cochrane-validated. NNT=2. |
| General adult — circadian entrainment / delayed sleep phase | 0.3–1.0 mg | 6 PM (or 1–2h before target sleep time) | Sublingual preferred, or oral IR | Clinically validated protocol. Corrects timing, not just drowsiness. |
| General adult — acute trouble falling asleep | 3.0–5.0 mg | 30–60 min before bedtime | Sublingual or oral IR | Short-term only. Not for chronic insomnia management. |
| Older adults — waking in the night | 2.0 mg | 30 min before bedtime | Extended-release (PR) | Gradual release mimics nocturnal plateau. Delirium prevention evidence in hospital settings. |
| Athletes — evening recovery support | 5.0 mg | Evening only; >6 hours before next training session | Oral IR | Never within 6 hours of training. No performance enhancement — recovery only. |
| Children with ASD or ADHD (supervised only) | 0.5–1.0 mg | 30–60 min before bedtime | Low-dose oral liquid | Short-term, physician oversight mandatory. Behavioural interventions should always come first. |
Oral IR
~15%
Jet lag, acute sleep latency. Variable — depends heavily on CYP1A2 enzyme genetics.
~£5–10/month at 1 mg
Extended-Release
~15%
Sleep maintenance in older adults. Mimics nocturnal plateau. No faster absorption advantage.
~£10–15/month at 2 mg
Sublingual Lozenge
30–40%
Fast onset. Bypasses first-pass liver breakdown. Best general choice when cost-sensitive.
~£10–15/month
Oral Spray / Liposomal
80–95%
Maximum consistency. Best for low responders and severe circadian disorders. Most predictable dose delivery.
~£15–25/month
Verdict
Conditional — exceptional for jet lag and circadian disorders; insufficient evidence for chronic insomnia
Best Form
Sublingual lozenge or oral spray (80–95% absorbed vs 15% from standard tablets)
Jet Lag Dose
0.5–1 mg at destination bedtime for 3–4 nights (less than one-fifth of a standard 5 mg tablet)
Sleep Latency Dose
3 mg dissolved under the tongue, 30 minutes before bed
Key Drug Warning
Fluvoxamine (SEVERE) + Warfarin (HIGH) — see Safety section
Food Alternative
Tart cherry juice (0.05–0.2 mg per serving — sub-therapeutic, but supports sleep via other pathways)
Safety & Interactions
Fluvoxamine potently blocks the CYP1A2 liver enzyme that clears melatonin. Even a 1 mg dose can produce blood levels equivalent to 100+ mg in a normal person — causing extreme sedation and potential toxicity. Avoid this combination entirely, or use ≤0.1 mg under physician oversight.
Melatonin shares the CYP1A2/2C9 metabolic pathway with these anticoagulants, elevating INR and prothrombin time and increasing bleeding risk. Requires regular INR monitoring and mandatory physician oversight when combined.
Melatonin is immunostimulatory — it directly promotes T-cell activity, which can counteract immunosuppressive therapy in organ transplant recipients. Contraindicated in transplant patients.
May alter seizure threshold in some neurological conditions and potentially reduce anticonvulsant efficacy in paediatric populations. Strict neurological oversight required.
May interact additively (hypotension risk) or paradoxically elevate blood pressure in some hypertensive populations. Monitor if combining.
Additive effect on the central nervous system — worsens next-day grogginess, particularly at OTC doses. Avoid combining on nights where clear-headedness the next morning matters.
| Effect | How Common | Dose-Related? | What to Do |
|---|---|---|---|
| Next-day grogginess / hangover | Common at ≥3 mg | Yes | Reduce dose; switch to sublingual/spray for faster clearance |
| Headache | ~10% | Moderate | Usually resolves; try lower dose |
| Dizziness | Occasional | Yes | Lower dose; avoid operating machinery after dosing |
| Mild core temperature drop | All doses | No | Expected — part of the sleep preparation mechanism, not a problem |
| Vivid dreams | Occasional | Variable | Usually benign; reduce dose if distressing |
| Daytime sedation / performance decrement | High with daytime use | Yes | Never take within 6 hours of training or work requiring alertness |
Upper Limit
No formal upper intake level established — WHO, EFSA, and NIH have not set a UL (melatonin is classified as a neurohormone, not a micronutrient). No acute toxicity observed at doses up to 100 mg in Phase 1 trials. Voluntary guidelines advise using the lowest effective dose for the shortest necessary duration.
The Nuance
' width='800' height='400'/%3E%3C/svg%3E)
| Use Case | Form | Monthly Cost | Value |
|---|---|---|---|
| Jet lag / circadian entrainment | Oral IR or sublingual, 0.3–1 mg | £5–10 | Exceptional — best-validated use at lowest cost |
| Acute sleep latency | Sublingual, 3 mg | £5–8 | High — short-term tool, good evidence |
| Sleep maintenance (older adults) | Extended-release, 2 mg | £10–15 | Moderate — evidence-backed for specific population |
| Maximum absorption (low responders) | Oral spray / liposomal, 1 mg | £15–25 | Moderate — justified for confirmed non-responders to standard forms |
| Chronic generalised insomnia | Any | Any | Low — wrong tool; CBT-I is first-line and more durable |
Food Alternative
Tart cherry juice contains 0.05–0.2 mg of melatonin per serving — too low for circadian dosing, but supports sleep via other mechanisms (anthocyanins, tryptophan content). A valid adjunct, not a replacement. No food source reaches therapeutic melatonin doses.
Cross-Engine Note — Wearable Monitoring
Vector Intelligence Stream (2026-03-17): wearable sleep staging underestimates deep sleep by up to 43 minutes per night. For melatonin users tracking circadian improvement, overnight HRV is a more reliable proxy than sleep staging data. Melatonin's circadian effects can be monitored via HRV trends over 1–2 weeks, but sleep staging data should be interpreted with the systematic underestimation in mind.
Sources
Herxheimer A & Petrie KJ (2002 / 2006) — Cochrane Database of Systematic Reviews
NNT=2 for jet lag prevention; 0.5–5 mg at target-destination bedtime is the optimal jet lag protocol. The foundational evidence for melatonin's most validated indication.
George et al. (2025) — CNS Spectrums
Delirium prevention in elderly and hospitalised adults: RR = 0.60 (95% CI: 0.47–0.76). Supports 0.3–1 mg at 6 PM for circadian entrainment protocol.
Nnadi et al. (2025) — AHA Scientific Sessions
HR = 1.89 for incident heart failure in chronic melatonin users. Heavily confounded by indication — refractory insomnia itself is an independent CVD driver. Hypothesis-generating only.
Erland LAE & Saxena PK (2017) — Journal of Clinical Sleep Medicine
71% of melatonin supplements missed label claim by >10%. Content range: -83% to +478% of stated dose. 26% contained serotonin contamination. Critical quality control evidence.
López-Flores M et al. (2018) — Journal of Exercise Physiology Online
No athletic performance enhancement from melatonin. Reduced creatine kinase markers when taken in the evening (recovery support). Daytime dosing actively impairs performance and alertness.
Anonymous / PMC Authors (2025)
Long-term high-dose melatonin (40–200 mg) in elderly with comorbidities — improved hypertension and ischemic heart disease markers. Hypothesis-generating only; no control group, supraphysiological doses, narrow population.
How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.
Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.
Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.
Get the protocolConviction-scored verdicts on supplements, nutrition, training, physio, and recovery.